ABSTRACT
The efficacy of acetylsalicylic acid (ASA) to prevent thrombotic or embolic events in patients with atherosclerosis was demonstrated in many large trials. Despite this fact, a subpopulation of patients experiences acute myocardial infarction or cerebrovascular ischemia indicating a nonresponsiveness to ASA. These patients would be candidates for an alternative or additional antiplatelet therapy, if they could be reliably identified. The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy.
Considerable progress has been made in the measurement of platelet function. One of the novel devices employed is the platelet function analyzer PFA-100, which was already tested in several studies involving patients with atherothrombosis to detect nonresponsiveness to ASA. Many of these investigations indicate that the PFA-100 could be used for routine identification of nonresponders to ASA and-probably also-for tailoring antiplatelet therapy. The aim of this article is to summarize the data obtained from the studies focusing on the monitoring of ASA therapy by the PFA-100.
KEYWORDS
PFA-100 - platelet function test - acetylsalicylic acid - ASA - monitoring
REFERENCES
-
1
Antiplatelet Trialists’ Collaboration .
Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
BMJ.
1994;
308
81-106
-
2
Antiplatelet Trialists’ Collaboration .
Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy.
BMJ.
1994;
308
159-168
-
3
Antiplatelet Trialists’ Collaboration .
Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.
BMJ.
1994;
308
235-246
-
4
Helgason C M, Bolin K M, Hoff J A et al..
Development of aspirin resistance in persons with previous ischemic stroke.
Stroke.
1994;
25
2331-2336
-
5
Vejar M, Fragasso G, Hackett D et al..
Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina.
Thromb Haemost.
1990;
63
163-168
-
6
Mammen E F, Comp P C, Gosselin R et al..
PFA-100 system: a new method for assessment of platelet dysfunction.
Semin Thromb Hemost.
1998;
24
195-202
-
7
Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A.
Description of an in vitro platelet function analyzer-PFA-100.
Semin Thromb Hemost.
1995;
21(Suppl 2)
106-112
-
8
Grotemeyer K H.
Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients.
Thromb Res.
1991;
63
587-593
-
9
Hurlen M, Seljeflot I, Arnesen H.
The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction.
Scand Cardiovasc J.
1998;
32
233-237
-
10
Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V.
Influence of ABO blood groups on primary hemostasis.
Transfusion.
2001;
41
56-60
-
11
Lippi G, Franchini M, Brocco G, Manzato F.
Influence of the ABO blood type on the platelet function analyzer PFA-100.
Thromb Haemost.
2001;
85
369-370
-
12
Dalby M C, Davidson S J, Burman J F, Davies S W.
Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser.
Platelets.
2000;
11
320-324
-
13
Feuring M, Haseroth K, Janson C P, Falkenstein E, Schmidt B M, Wehling M.
Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100).
Int J Clin Pharmacol Ther.
1999;
37
584-588
-
14
Gum P A, Kottke-Marchant K, Poggio E D et al..
Profile and prevalence of aspirin resistance in patients with cardiovascular disease.
Am J Cardiol.
2001;
88
230-235
-
15
Peters A J, Borries M, Gradaus F, Jax T W, Schoebel F C, Strauer B E.
In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.
J Thromb Thrombolysis.
2001;
12
263-272
-
16
Christiaens L, Macchi L, Herpin D et al..
Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease.
Thromb Res.
2002;
108
115-119
-
17
Macchi L, Christiaens L, Brabant S et al..
Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate.
Thromb Res.
2002;
107
45-49
-
18
Gianrossi R, Detrano R, Mulvihill D et al..
Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis.
Circulation.
1989;
80
87-98
-
19
Ashley E A, Myers J, Froelicher V.
Exercise testing in clinical medicine.
Lancet.
2000;
356
1592-1597
-
20
Lanza G A, Sestito A, Iacovella S et al..
Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina.
Circulation.
2003;
107
1378-1382
-
21
Andersen K, Hurlen M, Arnesen H, Seljeflot I.
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.
Thromb Res.
2002;
108
37-42
-
22
Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H.
Aspirin non-responder status in patients with recurrent cerebral ischemic attacks.
J Neurol.
2003;
250
63-66
-
23
Roller R E, Dorr A, Ulrich S, Pilger E.
Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100.
Blood Coagul Fibrinolysis.
2002;
13
277-281
-
24
Mueller T, Haltmayer M, Poelz W, Haidinger D.
Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease.
Vasc Endovascular Surg.
2003;
37
117-123
-
25
Jilma B.
Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.
J Lab Clin Med.
2001;
138
152-163
-
26
Grau A J, Reiners S, Lichy C, Buggle F, Ruf A.
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
Stroke.
2003;
34
849-854
-
27
Malinin A I, Atar D, Callahan K P, McKenzie M E, Serebruany V L.
Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease.
Eur J Pharmacol.
2003;
462
139-143
-
28
Grotemeyer K H, Scharafinski H W, Husstedt I W.
Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.
Thromb Res.
1993;
71
397-403
-
29
Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S.
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Circulation.
2002;
105
1650-1655
-
30
Ziegler S, Alt E, Brunner M, Speiser W, Minar E.
Influence of systemic inflammation on the interpretation of response to antiplatelet therapy, monitored by PFA-100.
Semin Thromb Hemost.
2005;
31
416-419
Prof. Dr.
M. Wehling
Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg
68135 Mannheim, Germany
Email: martin.wehling@kpha.ma.uni-heidelberg.de
